RxDoctor Payments Data

Virginia Walker

Psychiatric/Mental Health · Anchorage, AKNPI 1609326594

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.6% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 41.3% of the total. That places this record below the midpoint for psychiatric/mental health clinicians in AK, where the typical reported total is $371.

$371in general payments, 2019–2025

Across 14 payments — averaging $26.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$153
  • AbbVie$98
  • E.r. Squibb & Sons, L.L.C.$52
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$24
  • Otsuka America Pharmaceutical, Inc.$24
  • Alkermes, Inc.$20

What the payments were for

  • Food & beverage$34393%
  • Education$277%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$371 in reported general payments places this provider in the 50th percentile of 104 psychiatric/mental health providers in Alaska.

See all psychiatric/mental health providers in Alaska

Medicare billing

Part B allowed, 2024
$106,267
Medicare patients
351
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate44$328,221
Invega TrinzaPaliperidone Palmitate24$234,475
AustedoDeutetrabenazine13$137,433
Invega SustennaPaliperidone Palmitate20$67,642
Wellbutrin XlBupropion Hcl26$60,068
VraylarCariprazine Hcl37$50,718
Abilify MaintenaAripiprazole16$48,014
Lurasidone Hcl165$27,758
TrintellixVortioxetine Hydrobromide50$17,970
Aripiprazole362$13,258
LamictalLamotrigine13$9,103
Clozapine189$9,087
Asenapine Maleate79$8,899
Olanzapine601$8,594
Doxepin Hcl77$8,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$153$328,22144 claims
AbbVieVraylar$98$50,71837 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$24$48,01416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 104 psychiatric/mental health providers in Alaska.

Other psychiatric/mental health in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →